Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PKM | P14618 | 1/20 | 0.56 |
| ▸ | HTT | P42858 | 1/20 | 0.56 |
| ▸ | EPHX1 | P07099 | 2/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 8/20 | 0.54 |
| ▸ | GAA | P10253 | 2/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.54 |
| ▸ | MAPT | P10636 | 2/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.53 |
| ▸ | GLA | P06280 | 1/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.48 |
| ▸ | HPGD | P15428 | 1/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5538233 | 0.92 | NPSR1 (0.57) | HTTALDH1A1GAASMN1; SMN2MAPT | |
| SCHEMBL5530519 | 0.86 | POLB (0.58) | HTTALDH1A1GAASMN1; SMN2MAPT | |
| SCHEMBL5531686 | 0.81 | ALDH1A1 (0.58) | ALDH1A1GAASMN1; SMN2MAPTKMT2A | |
| SCHEMBL28595943 | 0.78 | PKM (0.66) | PKMHTTEPHX1ALDH1A1GAA | |
| SCHEMBL5529178 | 0.77 | POLB (0.55) | ALDH1A1GAASMN1; SMN2MAPTKMT2A | |
| SCHEMBL5527980 | 0.76 | MAPT (0.71) | EPHX1ALDH1A1GAASMN1; SMN2MAPT | |
| SCHEMBL29654104 | 0.76 | EPHX1 (0.72) | PKMHTTEPHX1ALDH1A1GAA | |
| SCHEMBL5529555 | 0.76 | EPHX1 (0.72) | PKMHTTEPHX1ALDH1A1GAA | |
| SCHEMBL5530231 | 0.75 | POLB (0.58) | ALDH1A1GAASMN1; SMN2MAPTKMT2A | |
| SCHEMBL5535333 | 0.74 | ALDH1A1 (0.55) | HTTEPHX1ALDH1A1GAASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070010671-A1 | Novel quinazoline derivatives and methods of treatment related to the use thereof | ARENA PHARMACEUTICALS, INC. | 2007-01-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070010671-A1 | Novel quinazoline derivatives and methods of treatment related to the use thereof | MCHR1, GPR119, MCHR2 | PKM 2314/4885HTT 583/4885EPHX1 1944/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.